<DOC>
	<DOC>NCT02949570</DOC>
	<brief_summary>To assess the efficacy of inecalcitol in combination with imatinib in CML patients with molecular residual disease on imatinib monotherapy.</brief_summary>
	<brief_title>Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study</brief_title>
	<detailed_description>To determine: - Duration of response - Progression free survival - Proportion of responders 2 years after discontinuation of inecalcitol - Duration of response after discontinuation of inecalcitol and imatinib - Bone remodelling effect - Safety of inecalcitol in combination with imatinib - Quality of Life</detailed_description>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Men or women aged of at least 18 years at the time of informed consent signature; Patients have signed written informed consent; ECOG performance status &lt; 2; Patients with Philadelphia chromosome positive chronic phase CML and M BCRABL transcript positivity (e13a2 or e14a2); Treatment with imatinib for more than 2 years (a history of treatment with interferon is tolerated); Patient in complete cytogenetic response with BCRABL/ABL status between 0.1% International Scale (IS) and 0.01% IS and no BCRABL checkpoint in the last six months better than Molecular Response MR4 ( i.e. BCRABL ratio &lt; 0.01% IS); Women of child bearing potential have a negative pregnancy test prior to first dose and agree to practice effective contraception during the study; Fertile men agree to practice effective contraception during the study; Patients agree to comply with the study requirements and agree to come to the clinic for required study visits; Patients agree to follow medication restrictions during the study; Expression of unusual BCRABL transcripts (other than e13a2 or e14a2); Pregnant or lactating women; Participating in another clinical trial with any investigative drug within 30 days prior to study enrolment(except for OPTIM imatinib); Treatment with interferon within the last 24 months; Imatinib dose modification within the last 3 months; Prior history of haematopoietic stem cell transplantation; Impaired renal function with creatinine clearance &lt; 30 ml/min/1.73m² according to the MDRD formula; Hypercalcemia (corrected with albuminemia); History of diseases known to be associated with calcium disorders: ongoing hyperparathyroidism, sarcoidosis….; Presence or history of symptomatic kidney stones in the last 5 years; Current use of drugs known to influence serum calcium (such as thiazide diuretics, teriparatide, calcitonin and multivitamin supplements containing &gt; 400 IU of vitamin D or calcium); Current use of digitalis; Current use of drugs which could influence bioavailability of inecalcitol (such as magnesiumcontaining antacids, bileresin binders); Patients with a chronic condition which is not well controlled that, according to the investigator, would interfere with the completion of the study; Use of any other experimental drug, therapy or vitamin D supplementation within 30 days of first inecalcitol administration; Patients with a mental deficiency preventing proper understanding of trial protocol requirements;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>